Alzheimer’s disease is a progressive brain condition that develops gradually over time, affecting memory, thinking, and the ability to perform everyday activities. It is the most common cause of dementia and is associated with the buildup of abnormal proteins in the brain that interfere with normal communication between nerve cells. One of the hallmarks of Alzheimer’s disease is the accumulation of amyloid-beta (Aβ) proteins. These proteins can cluster together to form toxic aggregates and plaques, which disrupt communication between neurons and contribute to cognitive decline.
Research has also identified another important protein involved in this process called Galectin-3 (Gal-3). Gal-3 has been found at elevated levels in the brains of individuals with Alzheimer’s disease and is believed to play a role in promoting inflammation and encouraging amyloid-beta proteins to clump together. By acting as a binding scaffold, Gal-3 may contribute to the formation and persistence of harmful amyloid aggregates that impair synaptic function.
TB006 is an investigational monoclonal antibody designed to specifically target Gal-3. By binding to Gal-3, TB006 is intended to interfere with its ability to support amyloid aggregation and inflammatory signaling. Through this targeted approach, TB006 is being studied for its potential to reduce harmful protein buildup, support healthier neuronal communication, and address multiple disease-related pathways involved in Alzheimer’s disease. While early research has provided encouraging insights, TB006 remains investigational and is not FDA-approved. Ongoing studies and expanded access use continue to help researchers and clinicians better understand its safety, tolerability, and potential clinical impact.
